AIMS: The mechanistic basis of the symptoms and signs of @entity296 in @entity1 without obstructive @entity453 ( @entity453 ) and evidence of @entity301 ( @entity301 ) is unclear. The aim of this study was to mechanistically test short-term late @entity1372 current inhibition ( @entity16590 ) in such subjects on angina, myocardial perfusion reserve index, and diastolic filling. MATERIALS AND RESULTS: Randomized, double-blind, placebo-controlled, crossover, mechanistic trial in subjects with evidence of @entity301 [invasive coronary reactivity testing or non-invasive cardiac magnetic resonance imaging myocardial perfusion reserve index (MPRI)]. Short-term oral @entity16590 500-1000 mg twice daily for 2 weeks vs. placebo. @entity951 measured by Seattle @entity951 Questionnaire (SAQ) and SAQ-7 (co-primaries), @entity951 (secondary), stress MPRI, diastolic filling, quality of life (QoL). Of 128 (96% @entity1 ) subjects, no treatment differences in the outcomes were observed. Peak heart rate was lower during pharmacological stress during @entity16590 (-3.55 b.p.m., P < 0.001). The change in SAQ-7 directly correlated with the change in MPRI (correlation 0.25, P = 0.005). The change in MPRI predicted the change in SAQ QoL, adjusted for body mass index (BMI), prior @entity583 , and site (P = 0.0032). Low coronary flow reserve (CFR <2.5) subjects improved MPRI (P < 0.0137), @entity951 frequency (P = 0.027), and SAQ-7 (P = 0.041). CONCLUSIONS: In this mechanistic trial among symptomatic subjects, no obstructive @entity453 , short-term late @entity1372 current inhibition was not generally effective for @entity951 . @entity951 and myocardial perfusion reserve changes were related, supporting the notion that strategies to improve ischaemia should be tested in these subjects. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01342029.

A randomized, placebo-controlled trial of late Na current inhibition ( XXXX ) in @entity301 ( @entity301 ): impact on angina and myocardial perfusion reserve.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial ischaemia'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CMD', 'coronary microvascular dysfunction'] @entity16590 :: ('MESH:C055512', 'Chemical') :: ['ranolazine'] @entity1372 :: ('MESH:D012964', 'Chemical') :: ['sodium'] @entity951 :: ('MESH:D000787', 'Disease') :: ['diary angina', 'Angina', 'SAQ angina'] @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease']
@entity16590 :: (MESH:C055512,Chemical) :: ['ranolazine']
